FX.co ★ TriSalus Life Sciences Prelim. Q4 Revenue Surges

TriSalus Life Sciences, Inc. (TLSI) reported a 44% rise in preliminary revenue for the fourth quarter, reaching approximately $8.3 million compared to the previous year. This growth is attributed solely to the success of the TriNav Infusion System, an innovative solution that addresses infusion barriers in solid tumors. Looking ahead, TriSalus projects revenue of approximately $29.4 million for the fiscal year 2024, representing a substantial year-over-year increase of nearly 59%. Further, the medical technology company anticipates maintaining this momentum with a projected revenue growth exceeding 50% for the full year 2025, aligning with previously provided guidance. At present, TriSalus shares have increased by 2.04%, reaching $5 on Nasdaq.